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In the past decades, new cancer treatment approaches for children and adolescents have led to a decrease in recurrence rates
and an increase in long-term survival. Recent studies have focused on the evaluation of the late effects on bone of pediatric
cancer-related treatments, such as chemotherapy, radiation and surgery. Treatment of childhood cancer can impair the
attainment of peak bone mass, predisposing to premature onset of low bone mineral density, or causing other bone side-
effects, such as bone quality impairment or avascular necrosis of bone. Lower bone mineral density and microarchitectural
deterioration can persist during adulthood, thereby increasing fracture risk. Overall, long-term follow-up of childhood cancer
survivors is essential to define specific groups at higher risk of long-term bone complications, identify unrecognized long-term
adverse effects, and improve patient care. Children and adolescents with a cancer history should be carefully monitored, and
patients should be informed of possible late complications of their previous medical treatment. The International Osteoporosis
Foundation convened a working group to review the bone complications of pediatric cancer survivors, outlining
recommendations for the management of bone health, in order to prevent and treat these complications.
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Introduction
During the past 30 years, changes in the treatment of children
and adolescents with cancer have led to substantial improve-
ments in survival, with a 5-year survival rate of childhood cancer
close to 80% [1]. This results in an increasing number of child-
hood cancer survivors (CCSs) who received cancer treatment
during growth. On the other hand, CCSs are at substantial risk of
late adverse effects of cancer treatment. The adverse events can
systemically involve the whole organism, including the cardiac,
gastrointestinal, genitourinary, musculoskeletal, neurological,
and pulmonary systems, as well as the endocrine system, skeletal
maturation and growth, sexual development, fertility, and repro-
duction. CCSs are also at an increased risk of secondary neo-
plasms, and cognitive and emotional impairments [2–8].
Although childhood cancers and their treatments have been
shown to impact bone health, there are limited data on this topic
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[9]. Endocrine, metabolic, and skeletal sequelae are among the
most frequently described complications, affecting between 20%
and 50% of subjects [10–14]. All cancer therapies can decrease
bone mineral density (BMD) through long-term endocrine alter-
ations, such as gonadal dysfunction, growth hormone (GH) defi-
ciency, and altered body composition [15–19]. These therapies
can also directly affect bone cells. Furthermore, modifiable fac-
tors, such as nutritional deficiency and less physical activity, can
modify bone mass and quality.
The aim of this study is to review bone complications in CCSs
and propose recommendations for the management of bone
health in these patients.
Materials and methods
The International Osteoporosis Foundation convened a working
group to review the literature regarding bone health in childhood
cancer and propose recommendations for the management of
bone health in CCSs. As in previous initiatives and publications,
the International Osteoporosis Foundation (IOF) working group
consists of clinical scientists and experts in the field of bone me-
tabolism and oncology.
Randomized controlled studies, prospective–retrospective
studies, case–control studies, cohort studies, systematic
reviews, and meta-analyses published from 1992 to 2017 were
searched on PubMed using the following search terms: (i)
osteopenia, osteoporosis, fragility fracture, bone mineral dens-
ity; (ii) acute lymphoblastic leukemia, Hodgkin and non-
Hodgkin lymphomas, osteosarcoma, Ewing’s sarcoma, chon-
drosarcoma, brain tumors, and neuroblastoma; (iii) hormonal
deprivation, glucocorticoids, physical activity, immobilization
and limb surgery, radiotherapy, chemotherapy, hematopoietic
stem-cell transplantation (HSCT), and calcineurin inhibitors;
(iv) guidelines, survivors of childhood cancers. Case reports
and case series were also included due to the limited evidence
available in the current literature. Only English-language
papers were reviewed. Letters, comments, editorials, expert
opinions, and personal communications were excluded. The se-
lection of studies was based on relevance to the broad scope of
this study. A list of the most important papers based on their re-
view of the literature was made, followed by a set of preliminary
recommendations graded according to the strength of underly-
ing evidence, based on the available guidelines, literature
reviews, and the expert opinions of the working group.
Subsequently, the plan of the manuscript, the recommenda-
tions, and the conclusions were further discussed. All positions
were graded on quality of evidence as High, Moderate, Low, or
Very low [Grading of Recommendations Assessment,
Development and Evaluation (GRADE); http://www.gradewor
kinggroup.org] [20].
The review contains four sections:
• Part I: Key points of peak bone mass and bone evaluation in
children and teenagers
• Part II: Bone health in CCSs
• Part III: Contributing factors of bone mass impairment in
CCSs
• Part IV: Recommendations for bone health in CCSs
Part I: Key points of peak bone mass and
bone evaluation in children and teenagers
Attainment of peak bone mass and assessment of
BMD
In young adults, BMD is dependent on peak bone mass (PBM)
[21, 22]. Patients treated for childhood or adolescent cancer may
not undergo optimal bone growth at puberty [22, 23]. An inad-
equate lean mass acquisition, weight-bearing physical activity,
and diet might also impair the attainment of PBM [21–26].
The World Health Organization (WHO) operational defin-
ition of osteoporosis on the basis of T-score is not applicable in
children and adolescents, in whom a Z-score, derived from age-
and sex-matched BMDs in a healthy population, should be used
[27]. Juvenile osteoporosis, referring to a BMD less than expected
for age in children and adolescents, has been defined as a BMD
>2 SD below the age- and sex-appropriate reference population
(Z-score < 2 SD) [27]. In 2013, the International Society for
Clinical Densitometry (IS-CD) proposed that the diagnosis of
osteoporosis in children and adolescents should not be made on
the basis of densitometric criteria alone, but that an overall assess-
ment of bone health, such as the presence of fractures due to low
trauma, should also be considered (http://www.iscd.org/official-
positions/2013-iscd-official-positions-pediatric/)[28]. On the
other hand, a BMD Z-score > 2.0 does not preclude the possi-
bility of skeletal fragility and increased fracture risk (http://www.
iscd.org/official-positions/2013-iscd-official-positions-pediatric/
). Moreover, the Official Position stated that in children with
short stature or growth delay, spine, and total body less head
BMC and areal BMD (aBMD) results should be adjusted (for the
spine, adjustment is recommended using either bone mineral ap-
parent density or the height Z-score; for total body less head,
adjusted using the height Z-score) [29, 30]. Finally, in children
for whom other sites are not measurable, lateral distal femur
scans by dual-energy X-ray absorptiometry (DEXA) are often
feasible, and the recent availability of reference data for lateral
distal femur for use in children is an important advance [31].
Quantitative computed tomography (QCT), evaluating volu-
metric BMD and trabecular and cortical bone compartments,
requires much higher radiation doses than DEXA, and is there-
fore difficult to use in children. A more powerful tool is the high-
resolution peripheral QCT, which evaluates, at the distal forearm
and tibia, the cortical and trabecular microarchitecture and den-
sities with a resolution up to 82 mm [32]. The radiation is lower,
but the technique is complex, particularly for growing bones, and
it therefore remains a research tool.
Role of sex hormones
Estrogen has a role for attaining PBM in both sexes, as demon-
strated by the lower BMD in young females with late menarche,
as well as in males with loss-of-function mutations in the estro-
gen receptor a gene and aromatase gene [33–37]. On the other
hand, androgens enlarge the cross-sectional area of long bones
that increase mechanical strength, may promote trabecular bone
development and thickness in young adulthood, subsequently
promote cortical consolidation in midlife, and maintain cortical
thickness and trabecular bone volume in older men through the
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stimulation of periosteal apposition and trabecular bone forma-
tion [37, 38].
Bone remodeling as assessed by bone turnover
markers
Morning fast serum procollagen type I N propeptide (s-PINP)
and serum C-terminal telopeptide of type I collagen (s-CTX) are
recommended by the IOF and the International Federation of
Clinical Chemistry (IFCC) for the evaluation of bone turnover
[39]. Current findings in cancer-treated children show decreased
bone formation and increased bone resorption [40]. However,
the evaluation of biomarkers in these patients can be difficult be-
cause of the lack of reliable reference values and their large varia-
tions according to age, gender, or pubertal stage [40]. Bone
biomarker data from longitudinal prospective studies on cancer-
treated children and long-term survivors are lacking. Alterations
in bone metabolism markers and growth deficits during therapy
may display a trend to recovery in the long term. These findings
are confirmed in adults treated for childhood cancer, who
showed reduced BMD and even asymptomatic vertebral frac-
tures, but no evident differences in bone turnover between
patients and a control group [41, 42].
Part II: Bone health in CCSs
Osteopenia/osteoporosis in CCSs
The prevalence of osteopenia and osteoporosis in CCSs is not yet
well documented. Moreover, the occurrence of fractures is still
insufficiently characterized among CCSs [11, 43]. Supplementary
Table S1, available at Annals of Oncology online, summarizes the
main studies on CCSs and bone status. Some pediatric cancer
treatments, listed below, are no longer used in current treatment
protocols; however, it is important to report them for CCSs.
Acute lymphoblastic leukemia. Acute lymphoblastic leukemia
(ALL) is the most common malignancy in childhood, and most
data on low BMD in CCSs are focused on this type of cancer. The
disease process per se and its treatments, such as high cumulative
doses of steroids, methotrexate, HSCT, cranial and testicular ra-
diation, are all potential risk factors for BMD deficits [14]. In
summary, during treatment of pediatric forms of ALL, low BMD
is commonly described, as well as reduced levels of bone forma-
tion markers, and this may lead to an increase of fracture inci-
dence [44–47]. A prospective cohort study, conducted within the
STeroid-associated Osteoporosis in the Pediatric Population
(STOPP) research program, showed that children with ALL had a
high incidence of vertebral fractures after 12 months of chemo-
therapy, and the presence of vertebral fractures and reductions in
spine BMD Z-scores at baseline were highly associated clinical
features [48]. The STOPP research program showed that verte-
bral compression was an under-recognized complication of
newly diagnosed ALL, and whether the fractures will resolve
through bone growth during or after leukemia chemotherapy
remains to be determined [49].
Rayar et al. enrolled children and adolescents with ALL at the
time of the first clinical remission. Twenty-three (18.5%) patients
developed fractures, but the fracture sites were not reported.
Older age and lower LS-BMD at diagnosis were predictors of
lower LS-BMD during continuation therapy, and dexamethasone
and lower LS-BMD were associated with fractures. The authors
concluded that using these variables could be feasible to develop
a predictor model to define the risk of bony morbidity in children
receiving ALL therapy [50]. Mostoufi-Moab et al. [51] conducted
a longitudinal assessment of BMD and bone structure in child-
hood survivors of ALL without cranial radiation. Their findings
suggested that ALL treatment in childhood without cranial radi-
ation may not result in long-term detrimental effects on bone de-
velopment. However, given the lack of complete normalization
of trabecular and cortical BMD, future studies are needed to con-
firm complete BMD recovery, and additional investigations
would be useful to find a connection between changes in bone
outcomes to short- and long-term fracture risk [51].
Finally, regarding the long-term effects of allogeneic BMT
(bone marrow transplant) on bone, the whole-body bone mass
tends to be only marginally lower in BMT patients than in ALL
survivors treated without BMT, and the size-adjusted bone mass
(BMC for bone area) remains normal [52].
Hodgkin and non-Hodgkin lymphomas. Regarding bone health
in childhood Hodgkin and non-Hodgkin lymphomas, most
studies were conducted long after completion of therapy [24].
Most patients treated for childhood malignant lymphomas had
no apparent deficits in bone mass and tended to maintain their
normal BMD during follow-up [24]. Therefore, childhood
lymphoma survivors appear to be only at negligible risk for lower
BMD [52].
Osteosarcoma. Osteosarcoma is the most common primary ma-
lignant bone tumor in children and adolescents. The introduc-
tion of neoadjuvant chemotherapy has improved the survival and
limb-salvage rate by decreasing the tumor burden before surgery
[53]. The long-term survivors of osteosarcoma usually have lower
PBM, with premature osteopenia/osteoporosis, and higher frac-
ture risk [54–56]. Moreover, most young patients with osteosar-
coma could fail to achieve optimal lean mass, because of
chemotherapy, nutritional deficits, and reduced physical activity
levels during and after treatment [42, 54–56].
Ewing’s sarcoma. Ewing’s sarcoma is another common primary
skeletal malignancy in childhood, usually treated with chemo-
therapy, surgery, and local radiation therapy [57]. Treatment reg-
imens have led to survival rates approaching 70% of patients with
no metastases at diagnosis. Low BMD and risk of fractures can
occur due to chemotherapy and limited mobility. The risk of frac-
tures could be associated with bone microarchitectural changes,
but further studies should be conducted [56].
Chondrosarcoma. Chondrosarcoma is a malignant bone tumor
but is uncommon in children. The standard treatment consists of
a wide resection or aggressive curettage, only for selected low-
grade extremity chondrosarcomas, and is usually not followed by
conventional adjuvant treatment [58]. Very little data exist on
effects on bone health.
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Other childhood tumors: brain tumors and neuroblastoma. BMD
has been reported to be reduced in up to one-third of survivors of
childhood brain tumors [59]. Children with brain tumors are
subject to several risk factors, such as decreased physical activity,
glucocorticoid treatment, GH deficiency, hypogonadotropic
hypogonadism due to cranial–spinal irradiation. The latter is
probably the most important risk factor [59, 60]; however, fur-
ther studies are necessary.
Finally, some data are also available on bone complications
(short stature and osteopenia) in neuroblastoma, an embryonic
malignancy of early childhood treated with high-dose therapy
and HSCT [61].
Part III: Contributing factors of bone mass
impairment in CCSs
Figure 1 summarizes the main contributing factors of bone mass
impairment in CCSs, which are described below.
Hormonal deprivation
In both sexes, the degree of gonadal impairment due to cancer
treatment is related to the age, dose, and fractionation schedule
for radiation therapy and chemotherapy, and it can negatively af-
fect PBM and bone mass [10, 11, 28, 34, 35, 62, 63]. Moreover, in
young females, GnRH agonists can be used for short-term use in
patients with estrogen-dependent tumors. Overall, standard
GnRH agonist treatment regimens of 6 months cause significant
bone loss in both the trabecular and cortical bones [64]. After
treatment discontinuation, bone loss recovers slowly, but may
not be completely recovered in all women [64]. Specific future
investigations on CCSs and the usefulness of treatment to prevent
bone loss could be valuable.
Moreover, GH deficiency (GHD) is a major side-effect of
radiotherapy and has a negative effect on BMD. GHD can lead to
decreased bone turnover, delayed growth in children, low PBM,
and increased fracture risk in adults [10, 65, 66].
Glucocorticoids
Glucocorticoids have a central role in the treatment of most
childhood tumors. Their effects on bone metabolism have been
widely studied, both in adults and in children [13, 67, 68]
(Figure 2). In the cancer setting, the use of steroids is rarely con-
tinuous with chemotherapy programs, but a relatively high dose
is common, either to prevent side-effects such as nausea and al-
lergy or to potentiate anticancer drugs. Thus, the attributable
part of bone quantity/quality reduction due to steroids is less easy
to evaluate, and probably depends on the dose itself, but also time
of exposure, cumulative dose, or compounds used [10, 67].
Physical activity, immobilization, and limb surgery
Decreased physical activity or the immobilization in subjects
with childhood cancer and CCSs increases bone resorption and
negatively affects BMD [23, 24, 28, 54]. However, skeletal
responses to disuse can be highly variable [23].
Depending on the sites where the surgery is carried out, its
effects will, of course, be different [70]. Limb reconstructions in
children usually have a long functional recovery. Patients must be
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Figure 1. The main contributing factors of bone mass impairment in childhood cancer survivors. The following factors can negatively affect
the bone health status of childhood cancer survivors: an inadequate diet, especially characterized by calcium and vitamin D deficiency, pro-
longed treatments with glucocorticoids, failure to achieve sufficient bone mass peak, hormone alterations involving growth hormone and/or
gonadal hormones, reduced or absent physical activity, cancer treatments including chemotherapy, radiotherapy, stem-cell transplantation,
and last, the inflammation and altered secretion of cytokines due to cancer cells. Furthermore, the achievement of the peak bone mass, a
fundamental factor for bone mass in adulthood, can be negatively influenced by prolonged use of corticosteroids, hormonal deficits impli-
cated in skeletal growth, and limitations of motor function.
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immobilized with consequent disuse osteoporosis. This is a
feared consequence that could cause implant failures and frac-
tures. Moreover, as a consequence of immobilization, the stiff-
ness of soft tissues and the poor compliance of sick children
trigger a vicious circle that delays the healing of weight-bearing
bones [13]. Care should be taken to ensure rapid healing of
orthopedic reconstruction in an interdisciplinary fashion, even if
the literature remains quite limited in this field.
Radiotherapy
Radiotherapy is an integral therapy to the treatment of several
childhood cancers, including leukemia, lymphoma, brain
tumors, sarcomas, neuroblastoma, and nephroblastoma (Wilms
tumor) [70, 71]. The risk of late effects from radiation treatments
depends on the radiation source, field, cumulative dose, volume,
and fractionation, as well as sex and age at the time of treatment
[2, 70]. It is mainly cranial, orbital, infratemporal, and nasopha-
ryngeal irradiation that can cause radiation-induced hypothal-
amic-pituitary injury, leading to GHD and central
hypogonadism [72]. Alone or in combination with alkylating
agent chemotherapy, it can also cause peripheral hypogonadism
in case of pelvic, whole-abdomen, and lumbar/sacral spine radi-
ation [73]. These endocrine alterations can affect bone growth,
bone mass acquisition, and low BMD [74]. Local radiation doses
of 40 Gy have been associated with hyperthyroidism [75],
which can induce bone loss by activation of osteoclast activity
[13]. Finally, some studies suggest that local and total body ir-
radiation may affect BMD directly by damaging the bone marrow
stroma, but others show conflicting findings [76–78].
In addition, other systemic dysfunctions involve cardiovascu-
lar, cerebrovascular, gastrointestinal, hepatic, pulmonary, repro-
ductive, and urinary systems. Neurocognitive, neurosensory, and
neurological deficits can occur [70]. The most common sites at
risk of subsequent neoplasm include bone [70, 79], in addition to
skin, breast, thyroid, and central nervous system [70].
Chemotherapy
The most commonly used chemotherapeutic agents in childhood
cancer include alkylating agents, antibiotics, and antimetabolites
[70, 80]. The risk for late effects depends on the cumulative dose,
route of administration, treatment schedule, and the sex and age
of the patient [70].
BMD is usually low in children treated with different chemo-
therapeutic regimens [45, 81]. Methotrexate has been consistent-
ly associated with reduced BMD in children treated for childhood
cancer [82]. Through a cytotoxic effect on osteoblasts, this drug
has been associated with reduced bone volume and impaired
bone formation. It is unclear whether there is a synergistic effect
Glucocorticoids
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Figure 2. The effects of glucocorticoids on bone. The figure shows the effects of glucocorticoids on bone cells and other organs/systems.
Bone cells: Glucocorticoids have mostly inhibitory effects on osteoblasts and osteocytes, inhibiting bone formation and decreasing the repair
of microdamaged bone. Moreover, glucocorticoids have stimulatory effects on osteoclasts, with consequent increase of cell recruitment and
differentiation, followed by bone reabsorption. However, the effects by glucocorticoids on osteoclasts are less evident compared with effects
by osteoblasts on osteoclasts mediated by RANKL and M-CSF. Other organs: The increase of bone reabsorption due to glucocorticoids is also
mediated by the effects of glucocorticoids on other organs, described below. In fact, glucocorticoids have catabolic effects on muscle, with
the consequent reduction of bone load (in addition to an increased fracture risk due to muscle weakness); in the intestinal tract they reduce
the absorption of vitamin D; in the renal tubule they decrease calcium reabsorption and increase 24-hydroxylase activity; and last, gonado-
tropin secretion can be reduced, leading to a loss of sex steroids. RANKL, receptor activator of nuclear factor kappa-B ligand; M-CSF, macro-
phage colony-stimulating factor; OPG, osteoprotegerin; ", increase; #, decrease; (), inhibitory effect; (þ), stimulatory effect [68, 69].
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of methotrexate and steroids, as they are given together in the
treatment of ALL [83]. In children treated for ALL, low doses of
methotrexate suppress osteoblast activity and stimulate osteo-
clast recruitment [84]. Higher cumulative doses of methotrexate
have been associated with a greater incidence of osteopenia [84].
In vitro studies with doxorubicin have described that it also has a
toxic effect on osteoblasts [85]. Several chemotherapy regimens,
such as methotrexate and cisplatin, are also nephrotoxic and may
cause skeletal abnormalities [86]. Moreover, ifosfamide can dam-
age renal tubular function and induce a Fanconi syndrome [87–
89]. In long-term survivors of ALL, ifosfamide has been found to
negatively affect BMD [73].
In addition to musculoskeletal abnormalities, it is known that
chemotherapy exposure has been associated with gonadal, urin-
ary tract, hepatic, cardiovascular, and neurocognitive and neuro-
sensory deficits, as well as pulmonary fibrosis. Finally, secondary
myelodysplasia and acute myeloid leukemia are also potential
late complications of chemotherapy [62, 70].
Hematopoietic stem-cell transplantation
Patients undergoing HSCT often receive multiple treatments (i.e.
methotrexate, steroids, total body irradiation, and high dose of
alkylating agents) and can display low BMD levels. It is unclear
whether there is additional risk from the transplant itself [52, 76,
90]. Moreover, as patients who have had an HSCT tend to have
more severe acute and chronic therapy-related complications,
they usually have additional risk factors, including poor nutri-
tion, decreased physical activity, and less exposure to sunshine. In
adulthood, transplant studies have shown 2%–10% loss of BMD,
with high risk of fracture [90].
Part IV: Recommendations for bone health
in CCSs
In 2018, the Children’s Oncology Group (COG) published an up-
date of long-term follow-up (LTFU) guidelines for survivors of
childhood, adolescent, and young adult cancer surveillance and
counseling recommendations (http://www.survivorshipguide
lines.org/pdf/2018/COG_LTFU_Guidelines_v5.pdf) [91–95].
The COG is the world’s largest organization devoted to clinical
trials and research of childhood and adolescent cancer [91]. In
Europe, there are three LTFU guidelines (in the UK, Scotland,
and Germany) [70].
Recommendations
Based on the literature review, the available guidelines, and our
experience, we propose the following evidence-based recommen-
dations for clinical practice regarding bone health in CCSs.
Figure 3 shows a summary of the diagnostic-therapeutic algo-
rithm of bone fragility for CCSs, which are explained and dis-
cussed in detail in the following paragraphs.
• The baseline assessment at entry into LTFU, which usually
occurs 2 years after the end of cancer therapy, potentially
damaging for bone health, should include a BMD evaluation
(grade of evidence: moderate), followed by laboratory exams,
in order to assess bone metabolism, renal function, and
factors inducing secondary osteoporosis (grade of evidence:
low). In case of young patients, BMD evaluation should be
carried out at specialized centers capable of interpreting pedi-
atric scans. Baseline anthropometric evaluations are useful to
check for growth disorders, bone deformations, or BMI alter-
ations that may have influenced bone health (grade of evi-
dence: low).
• Recommendations regarding adequate calcium (or diet in-
take) and vitamin D supplementations, in case of deficit, in
addition to adequate physical activity, to avoid negative life-
styles, should always be given, irrespective of BMD, as recom-
mended in the general population (quality of evidence: low).
Further studies are needed to establish the exact levels of vita-
min D and precise physical activity programs for this specific
population that may have an influence on skeletal growth
and maintenance of bone mass in adulthood.
• When low BMD (juvenile osteoporosis) is reported, Z-score
<2 or T-score <2.5 (based on age, pubertal development,
and growth process), and/or fragility fractures, and/or chron-
ic use of glucocorticoids, antiresorptive treatments
(bisphosphonate) should be taken into consideration (grade
of evidence in childhood/adolescent/young adult age: low;
grade of evidence in adulthood: moderate). Also, if necessary,
correction of endocrine alterations or other modifiable risk
factors of impaired bone quantity/quality should be evaluated
(grade of evidence: low). As, in most studies, BMDs in survi-
vors improve with increasing time-off therapy, and if hormo-
nal deficiencies are corrected, repeat measurements in case of
normal results (BMD Z-score > 1) should not be necessary
(grade of evidence: low).
In the following paragraphs, the recommendations are further
discussed, subdividing them into ‘Assessment and Monitoring’
and ‘Prevention and Treatment’.
Assessment and monitoring
Bone mineral density. The frequency and severity of bone mineral
deficits reported for CCSs suggest that specific diagnostic and
treatment interventions during childhood and adulthood should
be undertaken.
Although reduced BMD after childhood cancer treatment
might recover spontaneously following cessation of therapy,
adults treated for childhood cancer frequently have reduced
BMD and an increased risk of fractures [9, 11, 15]. COG LTFU
guidelines recommend an initial evaluation of BMD by DEXA or
QCT at entry into LTFU and 2 years after completion of cancer
therapy for children treated with agents and or modalities predis-
posing to BMD decrease (i.e. methotrexate, corticosteroids, or
HSCT), or in case of survivors with GHD, hypogonadism,
delayed puberty, or hyperthyroidism.
We recommend the use of DEXA at the spine and femur, based
on age, to diagnose and monitor BMD changes in these patients.
The number of aBMD revaluations depends on the magnitude of
the ongoing risk of fracture, the magnitude of low aBMD, and
periods when significant clinical changes are expected [30].
Results from the baseline evaluation and possible treatment inter-
vention should then determine the frequency of subsequent
follow-ups (grade of evidence: moderate).
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The use of QCT should be avoided because of the higher radi-
ation dose applied (grade of quality: very low).
In the future, imaging methods based on magnetic resonance
imaging or bone densitometer using ultrasound, such as the recent
radiofrequency echography multi-spectrometry technique, may be
considered, especially in the pediatric population, to closely moni-
tor quantity and quality of the trabecular and cortical bone tissue.
However, such techniques must still be validated and standardized
in the pediatric population (grade of quality: very low).
Bone turnover markers. The interest of bone turnover marker
(BTM) levels, such as s-PINP and s-CTX, during LTFU in survi-
vors, should be further evaluated, and levels should be considered
in relation to age, skeletal growth, or recent fractures [39, 40].
Evaluation and monitoring of BTM concentrations can show the
bone turnover and effects of treatments on bone metabolism, but
the prediction of fracture risk independently from BMD still
needs stronger evidence on which to base practice (grade of qual-
ity: very low). Data demonstrating a predictive role of BTMs for
fracture risk in secondary osteoporosis are lacking [28, 40].
Moreover, BTM levels are influenced by several factors, such as
vitamin D, IGF-1, physical activity, and nutrition, which should
be taken into consideration [40].
Observational and intervention studies should still be carried
out to evaluate the application of these BTMs in these patients.
Prevention and treatment
Calcium and vitamin D supplementations and other recom-
mendations. Vitamin D [25-hydroxyvitamin D (25(OH)D)] defi-
ciency and insufficient calcium intake are common in pediatric
patients affected by cancers, and in CCSs mean values for serum
25OHD result in the deficient or insufficient range in some, but
not all studies [96–100]. They may benefit from adequate dietary
intake/supplementation of calcium and vitamin D (grade of qual-
ity: low), although the role of sub-optimal vitamin D and calcium
status in delayed recovery of bone mass after completion of can-
cer therapy requires further investigation [40, 101–107].
Regarding this, the dietary intake of calcium and vitamin D and
the dosages of eventual calcium and vitamin D supplementation
should be evaluated according to national guidelines. Indeed, the
wise and balanced choice of the recommendations to follow
depends on one’s individual health outcome concerns, age, body
weight, latitude of residence, dietary and cultural habits, making
the regional or nationwide guidelines more applicable in clinical
practice [108].
Long-term trials and intervention studies in these patients are
needed to see whether supplementation of vitamin D and calcium
can prevent increased morbidity from fractures not only in the
period directly following treatment but also later in life.
Moreover, it is important to counsel survivors to avoid smok-
ing, alcohol, cannabis, and excessive use of caffeine.
Physical activity. Physical activity, such as weight-bearing exer-
cise, is an important factor for BMD growth in children and
BMD maintenance in adults; therefore, it is recommended for
CCSs to perform regular physical activity, always taking into con-
sideration the patient’s clinical situation (grade of evidence: low)
[21, 104, 109]. Although physical activity and exercise have be-
come a cornerstone in the prevention and treatment of chronic
diseases such as osteoporosis, there are no data on the effects of
Baseline assessment
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Figure 3. The diagnostic–therapeutic algorithm of bone fragility for childhood cancer survivors. LTFU, long-term follow-up; BMD, bone mass
density; DEXA, dual-energy X-ray absorptiometry; 25(OH)D, 25-hydroxyvitamin D; iPTH, intact parathyroid hormone; ALP, alkaline phosphat-
ase; BTMs, bone turnover markers; s-PINP, serum-procollagen type I N propeptide; s-CTX, serum C-terminal telopeptide of type I collagen;
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; GOT, glutamic oxaloacetic transaminase; GPT, alanine aminotransferase; gamma-
GT, gamma glutamyl transferase; Hba1C, hemoglobin A1c; TSH, thyroid-stimulating hormone; SHBG, sex hormone-binding globulin; GH,
growth hormone; IGF-1, insulin-like growth factor 1; LH, luteinizing hormone; FSH, follicle-stimulating hormone; BMI, body mass index.
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regular exercise from randomized controlled trials aiming to re-
duce cancer- and therapy-related sequelae in CCSs. Future pro-
spective studies are necessary to elaborate adequate physical
training programs in childhood and in subsequent periods for
these patients [110].
Correction of endocrine alterations. Treatment of low BMD in
CCSs can also imply the correction of underlying diseases that
may exacerbate BMD deficits [10, 11].
In case of childhood cancer treatment that can alter the
GH–IGF-I axis, GH replacement in CCSs may be considered
[12, 32, 111]. However, in childhood, GH seems to be relatively
weak as a bone-targeted anabolic treatment outside of the GHD
setting. Therefore, considering the burden to children of multiple
injections, the potential side-effects, and uncertainties about the
longer-term safety, the benefits to prevent or treat osteoporosis
outside of hormone replacement therapy for GHD do not justify
its risks and costs [12, 112]. In adulthood, GHD may be associ-
ated with a decreased BMD, and BMC with an increased fracture
risk. Recombinant human GH replacement induces a progressive
increase in BMD for up to 5–7 years of treatment, but data on
longer follow-ups are limited (grade of evidence: very low) [113].
In case of suspected testosterone deficiency in young age, it is
advisable to seek specialist referral following no advancement in
Tanner stage over a 6-month period in order to avoid delayed re-
ferral in a population of survivors at high risk of pubertal failure
and consequent potential impairment of growth, metabolic
health, bone mineral accretion, and quality of life as a result of
testosterone deficiency [62]. The effect of testosterone replace-
ment therapy on bone health in boys with delayed puberty has
not been described. There are only a few studies conducted on
adult male subjects that have shown the benefits of testosterone
as replacement treatment [112]. Among male CCSs, limited data
exist on the influence of androgen insufficiency on BMD (grade
of evidence: very low) [11]. In case of testosterone deficiency, al-
though testosterone replacement treatment may be appropriate
in deficient patients following accepted endocrine guidelines, the
potential benefits and risks of treatment need to be considered
appropriately for each patient with cancer history [62, 114–119].
Among female survivors, estrogen replacement may prevent
sex hormone deprivation-dependent risk of low BMD, but find-
ings are not yet consistent across all studies (grade of evidence:
very low) [11].
Overall, survivors treated with one or more potentially gona-
dotoxic treatments, and their providers, should be aware of the
risk of premature ovarian insufficiency or testosterone deficiency
and its implications for future fertility. Regarding this, we refer to
the recommendations of ‘International Late Effects of Childhood
Cancer Guideline Harmonization Group (IGHG) in collabor-
ation with the PanCareSurFup Consortium’ [62].
Treatments to decrease bone fragility: bisphosphonates and
others. Bisphosphonates, inhibitors of bone resorption, are usual-
ly used in primary and secondary osteoporosis in adults, but in
some cases are administered for low BMD in childhood, mostly
in osteogenesis imperfecta [120]. Although bisphosphonates,
such as alendronate and pamidronate, have not been evaluated in
large groups of CCSs for safety and efficacy, several small studies,
especially in children with ALL, have described that their use
during and after the completion of chemotherapy can improve
whole body BMD as well as BTMs (grade of quality: low) [121–
125]. Supplementary Table S2, available at Annals of Oncology on-
line, summarizes findings regarding the main published studies,
based on expert opinion, on the use of bisphosphonates in pedi-
atric cancer patients, the doses that have been used, and adverse
events reported [121–125].
Overall, evidence is limited for recommending bone-specific
drugs such as bisphosphonates in young adults with secondary
osteoporosis [28]; the optimal duration of osteoporosis treat-
ment is controversial and there are no specific dosages recom-
mended for patients with pediatric cancers or CCSs. Regarding
adult osteoporosis, the therapy should be reviewed after 3–5 years
of treatment with bisphosphonates. Fracture risk should be reas-
sessed after a new fracture, regardless of when it occurs. There is
little evidence to guide decision making beyond 10 years of treat-
ment, and management options in such patients should be con-
sidered on an individual basis [126, 127].
Regarding side-effects, bisphosphonates may cause an acute
phase reaction after intravenous administration, and gastrointes-
tinal side-effects can occur with all orally administered
bisphosphonates [128]. In case of impaired renal function, an ap-
propriate dose reduction should always be considered. Risk fac-
tors of bisphosphonate-related osteonecrosis of the jaw include
duration of bisphosphonate treatment, intravenous administra-
tion, dental procedures (extraction/surgery), dental trauma/
prosthesis, and an underlying diagnosis of cancer; however, this
is rare and has not been described in the pediatric population to
date [121, 129]. As the half-life of bisphosphonates in bone may
be several years, concerns regarding the potential for long-term
effects in children have been raised, such as the risk of impaired
mineralization of bone, linear growth, and delayed bone healing
after orthopedic procedures [11]. However, until now, few data
exist supporting the risks of these adverse events in treated chil-
dren. We are also reassured of the benign nature of bisphospho-
nates in the growing skeleton by patients with osteogenesis
imperfecta who show normal bone growth but with slower
remodeling of the metaphysis of long bones [121].
Thus, in the case of children affected by cancer, and in CCSs
with low BMD or fragility fractures, the use of bisphosphonates
can be envisaged, as proposed in COG LTFU guidelines (grade of
evidence in childhood/adolescent/young adult age: low; grade of
evidence in adulthood: moderate). However, long-term con-
trolled studies with larger samples are needed to assess the risks
and benefits of bisphosphonates in children with low BMD, as
well as the long-term outcomes in adulthood.
Studies on the use of denosumab, a human monoclonal anti-
body that inhibits bone resorption by binding RANKL (receptor
activator of nuclear factor kappa-B ligand), should also be carried
out, in order to evaluate the effects on improvement of BMD and
reduction of the risk of fragility fractures in these patients.
Overall, pediatric data on safety and efficacy of denosumab are
limited, unlike adult subjects with osteoporosis, bone metastases,
or giant cell tumors. However, some evidence suggests that deno-
sumab may also be beneficial in children in terms of increasing
BMD, decreasing bone turnover, and preventing growth of cer-
tain skeletal neoplasms (grade of evidence: very low). As opposed
to bisphosphonates, denosumab does not incorporate into bone
matrix and bone turnover is not suppressed after its cessation.
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After drug discontinuation, denosumab’s effect on bone turnover
is rapidly reversible, representing an important key difference
from bisphosphonates. On the other hand, rebound increased
bone turnover has led to severe hypercalcemia in several pediatric
patients; therefore, further research is needed to clarify the use of
denosumab in young patients [130]. Moreover, this turnover re-
bound appears to be associated with a marked increase in verte-
bral fracture risk [131]. Recently, the European Calcified Tissue
Society formed a working group to perform a systematic review
of existing literature on the effects of stopping denosumab [132].
In adulthood, a re-evaluation should be carried out after 5 years
of denosumab treatment, and bisphosphonate therapy should be
considered to reduce or prevent the rebound increase in bone
turnover. However, as the optimal bisphosphonate regimen
post-denosumab is currently unknown, continuation of denosu-
mab can also be considered until results from ongoing trials be-
come available [132]. There are no data in pediatric populations,
and further studies are needed in this regard.
Finally, teriparatide [parathyroid hormone (1–34)], an anabol-
ic hormonal therapy approved for the treatment of severe osteo-
porosis in adults, does not represent a possible therapeutic
option in cancer patients (grade of evidence: high). Moreover, it
has a black box warning against its use in children, due to risk of
osteosarcoma [112].
Avascular necrosis of bone in childhood cancer
Childhood cancer patients are also at increased risk of avascular
osteonecrosis of bone (AVN), which can be a bone devastating
complication in some cases [133]. It occurs more frequently after
HSCT than after chemotherapy and/or radiotherapy [133–136].
Osteonecrosis is one of the most common therapy-related and
debilitating side-effects of antileukemic treatment. An innovative
approach to reduce osteonecrosis-associated morbidity might be
systematic early screening for osteonecrosis by serial magnetic
resonance images (grade of quality: very low) [137]. This is prob-
ably not realistic in routine daily practice. More research is
needed to determine whether genetic testing for patients at high
risk for developing AVN would reduce the morbidity associated
with this complication. There is no evidence-based consensus on
how osteonecrosis needs to be managed in pediatric ALL patients
[138].
Osteonecrosis among long-term CCSs is rare. However, a
retrospective cohort study described that CCSs had a significantly
increased relative rate compared with the healthy population, es-
pecially those who were older at diagnosis and received dexa-
methasone or radiation therapy. Future investigations are needed
to better delineate these results [139].
Discussion
Conclusions
CCSs have a multifactorial impact on bone fragility. Particular at-
tention during cancer treatment should be paid to reduce the im-
pact on future adult bone health. Once in remission or cured,
patients should undergo prolonged follow-up for bone fragility
to prevent fracture onset. More studies in large and homogenous
patient groups are needed to better quantify the BMD loss, inci-
dence of growth impairment, osteoporosis occurrence, fractures,
relationship between DEXA parameters and fragility fractures,
BTMs monitoring, and AVN in all childhood malignancies.
A useful research axis would be to identity groups at higher risk
of long-term bone complications, identify unrecognized long-
term adverse effects, and improve patient care. Early detection of
CCSs at high fracture risk should lead to adequate preventive or
therapeutic measures, aiming to decrease morbidity and health
costs, both at younger and older ages. For the multidisciplinary
team taking care of CCSs, the overall target remains the reduction
of cancer-related morbidity from treatment-induced bone loss in
the increasing population of adolescents and young adults who
have been adequately and successfully treated for childhood
cancers.
In the development of these recommendations, several sub-
stantial knowledge gaps for clinical research were revealed. Until
now, there have been no large observational or randomized trials
capable of determining whether improving bone health in CCSs
differs from the management of the general population with
bone disorders. Future research should be approached in a sys-
tematic manner by large single-institution studies, or internation-
al multicenter collaborative projects to fill the highlighted gaps.
In response to USA recommendations to improve evidence-
based follow-up care in these patients, a web-based support sys-
tem for clinical decision making, called the Passport for Care
(PFC), was recently developed [3]. The aim of the PFC is to foster
clinician–survivor conversations and decision making, enhanc-
ing screening and long-term follow-up care, and ultimately to
improve health outcomes, including bone health [3]. In some
European centers, an electronic tool called ‘Survivorship
Passport (SurPass)’ is used [140]. SurPass provides a summary of
each survivor’s clinical history, together with personalized
follow-up and screening recommendations based on guidelines
published by the IGHG and PanCareSurFup consortia [140,
141]. However, the ‘bone toxicity’ section of the IGHG is current-
ly not available. Finally, optimal survivorship care should include
an effective transition in care from pediatric to adult care; instead,
transition to adulthood is currently suboptimal [142]. A well-
coordinated transition of care is crucial for adherence to
follow-up, because young adults are particularly at risk of loss for
follow-ups, and adherence to late-effects screening decreases with
age. Until now, despite the need to improve communication
between pediatric oncology and primary care, only a few coun-
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